Borrowing Information across Subgroups in Phase II Trials: Is It Useful?
Authors:
Open Access
- 14 March 2013
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (6) , 1326-1334
Abstract
Because of the heterogeneity of human tumors, cancer patient populations are usually composed of multiple subgroups with different molecular and/or histologic characteristics. In screening new anticancer agents, there might be a scientific rationale to expect some degree of similarity in clinical activity across the subgroups. This poses a challenge to the design of phase II trials assessing clinical activity: Conducting an independent evaluation in each subgroup requires considerable time and resources, whereas a pooled evaluation that completely ignores patient heterogeneity can miss treatments that are only active in some subgroups. It has been suggested that approaches that borrow information across subgroups can improve efficiency in this setting. In particular, the hierarchical Bayesian approach putatively uses the outcome data to decide whether borrowing of information is appropriate. We evaluated potential benefits of the hierarchical Bayesian approach (using models suggested previously) and a simpler pooling approach by simulations. In the phase II setting, the hierarchical Bayesian approach is shown not to work well in the simulations considered, as there appears to be insufficient information in the outcome data to determine whether borrowing across subgroups is appropriate. When there is strong rationale for expecting a uniform level of activity across the subgroups, approaches using simple pooling of information across subgroups may be useful. Clin Cancer Res; 19(6); 1326–34. ©2012 AACR.Keywords
This publication has 17 references indexed in Scilit:
- The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering CommitteeClinical Cancer Research, 2010
- Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical ModelJournal of Clinical Oncology, 2009
- Phase II Study of Sorafenib in Patients With Metastatic or Recurrent SarcomasJournal of Clinical Oncology, 2009
- Multiple Histology Phase II TrialsClinical Cancer Research, 2009
- Bayesian clinical trials at the University of Texas M. D. Anderson Cancer CenterClinical Trials, 2009
- Practical Bayesian Design and Analysis for Drug and Device Clinical TrialsJournal of Biopharmaceutical Statistics, 2007
- Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypesStatistics in Medicine, 2003
- Bayesian Models for Gene Expression With DNA Microarray DataJournal of the American Statistical Association, 2002
- Approximate Bayesian Inference in Conditionally Independent Hierarchical Models (Parametric Empirical Bayes Models)Journal of the American Statistical Association, 1989
- Approximate Bayesian Inference in Conditionally Independent Hierarchical Models (Parametric Empirical Bayes Models)Journal of the American Statistical Association, 1989